tbuckley/cabot-search huggingface dataset:
Abstract 8702: Assessment of Coronary Artery Disease by Contraction Front Mapping Analysis with Real Time Three-dimensional Stress Echocardiography with Adenosine: A Comparison with Thallium Scintigraphy
Authors: Reiko Matsuoka, Masanori Kawasaki, Ryuhei Tanaka, Koji Ono, Takatomo Watanabe, Tomoko Fujii, Fumitaka Tokoro, Maki Nagaya, Noriyuki Onishi, Yoshifumi Kawai, Shintaro Abe, Yoshiaki Goto, Takashi Yoshizane, Takashi Kato, Syunichiro Warita, Tai Kojima, Makoto Iwama, Takeshi Hirose, Shintaro Tanihata, Toshiyuki Noda, Mami Iida, Sachiro Watanabe, Shinya Minatoguchi
Journal: Circulation (2011)

Background: Stress echo with adenosine is not routinely used for the assessment of coronary artery disease (CAD) because of insufficient accuracy. Visual estimation of dyssynchrony with 2-D echo is often difficult because delays &lt;70 ms cannot be detected with human eye. Contraction front mapping (CFM) constructed by real time 3-D echocardiography (RT3DE, ACUSON SC2000) with frame rate of 40 fps provides time-volume analysis for left ventricular (LV) volume, and enables us to assess LV dyssynchrony in only one heart beat. Thus, we evaluated usefulness of stress RT3DE for the detection of CAD. Methods : We performed scintigraphy and CFM at rest and stress with adenosine before angiography in 35 patients with suspected CAD. CFM can automatically divide LV into 16 segments, detect dyssynchrony and provide systolic dyssynchrony index (SDI) from the dispersion of time to minimum (min) regional volume for all 16 segments (average SDI) and maximum (max) dispersion of time to min regional volume (max SDI). Coronary angiography was served as a gold standard. Results : Images suitable for analysis were 34 (Figure). Heart rate and LV ejection fraction were increased at stress by 12% and 11% respectively. The prevalence of CAD was 76%. Diagnostic accuracy (88% for echo vs. 87% for scintigraphy), sensitivity (88% vs. 88%) and specificity (88% vs.85%) for the detection of CAD were similar between stress RT3DE and sintigraphy. There was no significant difference in the ability to detect single- or multi-vessel disease between RT3DE and scintigraphy. Although average SDI was similar at rest and at stress (6.6±4.0% vs.7.2±4.0%) max SDI was significantly increased at stress (22±10% vs. 18±8%, p&lt;0.05). Conclusion: CFM constructed by stress RT3DE as a promising technique to quantify LV dyssynchrony in only one heart beat confers similar diagnostic accuracy in detection of CAD to scintigraphy and may be useful in the clinical setting for the evaluation of patients with suspected CAD.
Impotence and Frigidity.
Authors: Donald W. Hastings
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Natural Antioxidant-Isoliquiritigenin Protects Heart against Ischemia-Reperfusion Injury via Activation of Cardioprotective Signaling Pathways
Authors: Xiaoyu Zhang, Jingying Wang, Wenguang Li, Ji Li
Journal: Circulation (2009)

P19: Natural Antioxidant-Isoliquiritigenin Protects Heart against IschemiaReperfusion Injury via Activation of Cardioprotective Signaling Pathways Xiaoyu Zhang1; Jingying Wang2; Wenguang Li3; Ji Li4 1 Lanzhou Univ, Sch of Basic Medicine Sciences, Lanzhou, China 2 Univ at Buffalo-SUNY, Buffalo, NY 3 Lanzhou Univ, Sch of Basic Medicine Sciences, Lanzhou, China 4 Univ at Buffalo-SUNY, Buffalo, NY Background: Isoliquiritigenin (ISL), a simple chalcone-type flavonoid, which is derived from licorice compounds and mainly present in foods, beverages and tobacco. ISL is a natural antioxidant. There is amount of evidence that reactive oxygen species (ROS) is a critical factor involved in cardiac damage and apoptosis associated signaling pathways during ischemia/reperfusion. We hypothesize that ISL as a natural antioxidant may protect heart against ischemic injury via scavenging ROS and regulating cardioprotective signaling pathways. Search: Advanced Search Go Circulation Home Subscriptions Archives Feedback Authors Help AHA Journals Home « Previous Article | Table of
Abstract 17440: Sonic Hedgehog Signaling Regulates Myogenic Stem Cells and Acts Upstream of Wnt Signaling During Limb Regeneration
Authors: Bhairab N Singh, Michelle J Doyle, Cyprian V Weaver, Naoko Koyano-Nakagawa Koyano-Nakagawa, Daniel J Garry
Journal: Circulation (2011)

Appendage regeneration in urodeles such as the newt occurs through formation and maintenance of multipotent progenitors called the blastema. The blastemal progenitors are regulated by the coordinated activity of transcriptional networks and signaling pathways. In the present study, we have investigated the role of sonic hedgehog (Shh) signaling in myogenic stem/progenitor cells during limb regeneration. We show that Shh signaling is essential for the limb regeneration and inhibition of Shh pathway leads to irreversible perturbation of regeneration. Our histological analysis and reversibility experiments suggest that although inhibition of Shh pathway does not affect the dedifferentiation process, it is required for the initial stages of regeneration. Using BrdU incorporation and immunohistochemical analyses, we show that Shh signaling regulates the blastemal cell proliferation, as inhibition of Shh pathway results in a 4-fold reduced labeling of BrdU positive nuclei and results in G0/G1 cell cycle arrest. We further show that limb regeneration is achieved by activation of Pax7 + myogenic stem cells, and Shh signaling inhibition leads to reduced number of Pax7 + cells. Importantly, we find that Shh inhibition leads to retarded migration of myoblast cells and reduced proliferation of the activated myoblasts (MyoD + cells). Further, we demonstrate using an inhibitor-activator strategy that activation of Wnt signaling could rescue the Shh inhibition. Analysis of cell cycle kinetics reveals that activation of the Wnt pathway in the Shh inhibition background results in increased G2/M populations, concomitant with a 23% increase in BrdU positive cells suggesting that the Wnt pathway is activated later than Shh signaling and modulates cell cycle regulatory networks. Collectively, our results demonstrate the hierarchical regulation of signaling pathways in the regulation of myogenic stem cell populations and limb regeneration.
Abstract 5607: Risk of Re-hospitalization for Patients Using Clopidogrel With a Proton Pump Inhibitor
Authors: Karen M Stockl, Lisa Le, Armen Zakharyan, Ann S Harada, Brian K Solow, Joseph E Addiego, Scott D Ramsey
Journal: Circulation (2009)

Background: Recent pharmacodynamic and retrospective clinical analyses have suggested that proton pump inhibitors (PPIs) may modify the antiplatelet effects of clopidogrel. Methods: We conducted a retrospective cohort study of persons enrolled in a large multi-state health insurance plan with commercial and Medicare clients to evaluate adverse clinical outcomes for patients using clopidogrel plus PPI compared to clopidogrel alone. Using propensity scoring methodology, patients discharged from the hospital for myocardial infarction (MI) or coronary stent placement and treated with clopidogrel plus PPI were matched 1:1 with patients with similar cardiovascular risk factors treated with clopidogrel alone. Re-hospitalizations for MI or coronary stent placement were evaluated over a period of up to 360 days. A subanalysis was conducted to study the impact of pantoprazole, the most prescribed PPI. Results: Rates of re-hospitalization for MI or coronary stent placement were higher for clopidogrel plus PPI versus clopidogrel alone (Table ). Patients receiving clopidogrel plus PPI had 92% higher risk of re-hospitalization for MI and 53% higher risk of re-hospitalization for MI or coronary stent placement than patients receiving clopidogrel alone. Increased risk of re-hospitalization for MI or coronary stent placement was also observed for the subgroup of clopidogrel plus PPI patients receiving pantoprazole. Conclusion: Patients receiving clopidogrel plus PPI had significantly higher risk of re-hospitalization for MI or coronary stent placement than patients receiving clopidogrel alone. Prospective clinical trials and laboratory analyses of biochemical interactions are warranted to further evaluate the potential impact of PPIs on the efficacy of clopidogrel. Rates and Risk of Hospitalization for MI or Coronary Stent Placement
Human Sex Anatomy. A Topographical Hand Atlas.
Authors: Robert Latou Dickinson
Journal: Annals of Internal Medicine (1972)

Fifty years of careful observation, notation and sketching of the organs of sex with correlation with clinical findings have resulted in this atlas of functional anatomy. This book is devoted chiefly to the anatomic relationships in the sex act. The increased recognition of the importance of sex education for the layman as an aid not only to successful marriage but to mental health is placing an additional stress on the physician. He must learn to give advice on a factual and scientific basis; in this way superstition and prurient ignorance will be defeated. However, much more is taught about the chemistry and histology of conception than the technics which bring it about. The Kinsey report reveals, despite its criticisms, that sex practice and theory may be quite divergent. How much better it is for the physician who advises on matters as vital as these that his knowledge be based on
Pharmacodynamic effect of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, on HDAC enzyme inhibition and histone acetylation induction in phase I clinical trials in patients (pts) with advanced solid tumors or non-Hodgkin’s lymphoma (NHL)
Authors: A. Kalita, C. Maroun, C. Bonfils, K. Gelmon, L. L. Siu, A. Tolcher, M. Carducci, J. M. Besterman, G. K. Reid, Z. Li
Journal: Journal of Clinical Oncology (2005)

9631 Background: Histone deacetylase inhibitors represent a new class of targeted anticancer agents. Deacetylation of histones by HDACs is postulated to inactivate tumor suppressor genes leading to neoplastic transformation. Thus, inhibition of these enzymes might restore normal growth control. Several HDAC inhibitors, including MGCD0103, are in clinical trials. Methods: To analyze the pharmacodynamic properties of MGCD0103 in Phase I clinical studies, we have used a variety of biological assays to monitor HDAC inhibitory activity. An HDAC enzyme assay using intact white cells from patients was used to monitor the enzyme inhibitory activity of MGCD0103, while histone acetylation in these cells was analyzed by Western blotting, fluorescence-activated cell sorting (FACS) and enzyme-linked immunosorbent assay (ELISA). Results: We demonstrate that, in 3 of the first 7 patients for whom comparative data are available, HDAC enzyme inhibition correlates positively with histone acetylation induction in their peripheral white cells. Conclusion: Preliminary results evaluating the effects of MGCD0103 on HDAC enzyme activity and on increased histone acetylation suggest that these methodologies may both be useful in assessing PD response to MGCD0103. The sensitivity and utility of these assays in PD studies of MGCD0103 in man as part of future clinical trials of HDAC inhibitors in general will be further discussed. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration MethylGene MethylGene
Abstract 15433: Prevalence and Natural History of Moderate or Severe Mitral Regurgitation: an Observational Study from a Single Center
Authors: Zainab Samad, Eric Yow, Linda K Shaw, Hussein R Al-Khalidi, Kristine Arges, John H Toptine, Mitchell Krucoff, Andrew Wang, James G Jollis, Eric J Velazquez
Journal: Circulation (2011)

Background: Mitral regurgitation (MR) is common and its management remains controversial despite diagnostic and surgical advances. Understanding the prevalence and natural history of moderate or se...
Abstract 6256: Absence of Leptin Resistance in Platelets from Obese Individuals Suggests a Mechanism for Increased Thrombosis Risk in Obesity
Authors: Claudia Dellas, Katrin Schaefer, Ilonka Rohm, Mareike Lankeit, Gerd Hasenfuss, Stavros Konstantinides
Journal: Circulation (2008)

Clinical studies have demonstrated that elevated leptin levels, such as frequently found in obesity, are an independent cardiovascular risk factor. We and others have shown that leptin promotes platelet aggregation and thrombosis. However, little is known about the existence of platelet resistance to leptin, particularly in the setting of obesity and central leptin resistance. In the present study, we examined the effects of leptin on platelet aggregation in morbidly obese subjects (n=40; BMI 41.6±1.1 kg/m2; leptin 49.7±3.4 ng/mL) in comparison to normal-weight controls (n=36; BMI 23.3±0.4; leptin 6.5±0.7). The aggregatory response to ADP was significantly increased in platelets from obese donors compared to controls as shown by a left-shift in the ADP dose curves. Thus, percent platelet aggregation at 2, 3, 4, and 5 μM ADP was 18.7±4.8 in the obese vs. 4.7±2.0 in controls (P=0.01), 37.2±6.6 vs. 17.1±4.4 (P=0.01), 60.8±6.0 vs. 37.8±6.5 (P=0.01), and 80.2±6.5 vs. 44.5±8.8 (P=0.002), respectively. Plasma leptin levels, but not the body-mass-index, were significantly higher in subjects with stronger (above the median) platelet aggregation in response to ADP compared to those with weaker (below the median) aggregation (35.9±5.1 vs. 22.4±4.1 ng/mL; P=0.04). In further experiments, exogenous leptin stimulation promoted ADP-induced platelet aggregation by 25% on average, and there was no difference in the responsiveness to leptin between platelets from obese and those from lean donors (controls; P=0.99). Using Western blot analysis we found that leptin induced phosphorylation of the signaling molecules JAK2 and STAT3 to a similar extent in platelets from both groups. Expression of potential mediators of leptin resistance (SOCS3 and PTP1B) also did not differ in platelets from obese and control subjects. Taken together, our data indicate that platelets from obese donors show increased aggregatory response to ADP, which might partly result from the increased circulating leptin levels. Platelets from obese individuals were not resistant to the enhancing effects of leptin on ADP-induced aggregation. Our results thus support the existence of a direct link between obesity, hyperleptinemia and thrombosis.
Inhibition Of Lyn and Syk By Treatment With Dasatinib, Fludarabine, and Rituximab Correlates With Apoptosis and Clinical Response In Patients With Relapsed CLL
Authors: Philip C. Amrein, Xin Kai, Carlos Donato, Jon Arnason, Jennifer R. Brown, Karen K. Ballen, Eyal C. Attar, Amir T. Fathi, Ephraim P Hochberg, HyukJoo Hwang, Lillian Werner, Donna Neuberg, Shiv Pillai
Journal: Blood (2013)
Zinc-finger transcription factor Slug contributes to the function of the stem cell factor c-kit signaling pathway
Authors: Jesus Pérez-Losada, Manuel Sánchez-Martı́n, Arancha Rodrı́guez-Garcı́a, Maria Luz Sánchez, Alberto Orfao, Teresa Flores, Isidro Sánchez-Garcı́a
Journal: Blood (2002)
A detailed analysis of von Hippel Lindau (VHL) mutations in sporadic clear cell renal carcinoma (ccRCC), VHL syndrome, and Chuvash polycythaemia.
Authors: L. Gossage, E. Cartwright, T. Eisen, M. Bycroft
Journal: Journal of Clinical Oncology (2010)

e15024 Background: Germline mutations in the VHL gene cause VHL syndrome. Functional loss of the VHL gene product, pVHL is also seen in the majority of cases of sporadic ccRCC and homozygosity for the germline R200W VHL mutation causes Chuvash polycythaemia, a benign congenital erythrocytosis. pVHL has many functions including the ability to target hypoxia-inducible factor (HIF) for polyubiquitylation and proteasomal degradation by forming the substrate recognition component of a ubiquitin-ligase complex. The development of ccRCC has been attributed to impaired HIF-α downregulation by pVHL mutants. However many point mutations within VHL which are associated with ccRCC are external to the HIF-α binding site. The structural and functional effects of the R200W mutation are unknown. Methods: We present a detailed biochemical analysis of pVHL mutant proteins identified in patients with sporadic ccRCC, type 2A (low risk of ccRCC) and 2B (high risk of ccRCC) VHL syndrome and Chuvash polycythaemia. Results: Type 2A mutations Y98H and Y112H are not globally destabilising, but affect the binding site for the HIF-α hydroxyproline, as revealed by localised chemical shift changes in NMR. Mutations at S65, N78, G93 and T157 have been described in both sporadic ccRCC and type 2B VHL syndrome and are not predicted to directly impact upon the HIF-α binding site. The G93V and S65L mutations cause extensive structural perturbations of pVHL which are likely to affect both HIF-α related and HIF-α unrelated functions of pVHL. In contrast N78D, T157I and R200W mutations cause minimal structural perturbations of pVHL and do not impair HIF-α binding, implying potential novel mechanisms of pathogenicity. Truncating mutations identified in patients with sporadic ccRCC result in fundamentally unstable proteins which retain the ability to bind HIF-α, supporting previous assertions suggesting a possible dominant negative role for truncated pVHL mutants. Conclusions: Increased knowledge with respect to the functional effects of mutational events within VHL will allow us to develop informative ways of categorising these events in a way which may ultimately provide novel therapeutic opportunities. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Cancer Research UK, Medical Research Council
Candid disclosure is right
Authors: L Strunin, J M Davies
Journal: BMJ (1995)

EDITOR,—At first reading we thought the editorial by Jean Ritchie and Sally Davies1 was in response to the wave of antilawyer jokes that has swept North America—for example, “What would you call 100 dead lawyers at the bottom of the sea?” “A good start”; the new version presumably is: “What would you call 100 …
An open label phase II trial of glufosfamide: A β-D-glucose-linked isophosphoramide mustard given as 1-hour infusion in patients with advanced breast cancer
Authors: G. F. Tidmarsh, I. O. Kudajbergenova, S. N. Navrusov, V. V. Stepula
Journal: Journal of Clinical Oncology (2004)

646 Background: Glufosfamide (Glufo) is a new alkylating agent in which the active metabolite is linked to β-D-glucose to target the glucose transporter system and increase intracellular uptake in tumor cells. The aim of this study was to evaluate the activity and the safety profile of Glufo administered as 2nd line chemotherapy in patients (pts) with metastatic and inoperable breast cancer. Methods: Pts received 5000 mg/m2 of Glufo as a 1-hour infusion every 3 weeks. Anti-tumor activity was assessed according to RECIST criteria and toxicity according to CTC 2.0. The study was approved by the appropriate ethical committees and pts gave written informed consent. Results: Twenty-two pts were included over a 20-month period and all pts received treatment (median age 51 years, WHO performance status 0/1/2: 1/9/12 pts). A total of 42 treatment cycles were administered in 22 pts. Anti-tumor activity: Partial response was observed in 3 of 22 pts (14%) for the ITT population (PP population 3 of 11 pts). Eight of 22 pts (36%) had stable disease. All responders previously failed cyclophoshpamide therapy. Safety profile: Myelotoxicity was generally mild not exceeding CTC grade 2. A decrease of creatinine clearance to CTC grade 3 was observed in 2 pts. Other CTC grade 3 adverse events "likely" or "not assessable " related to Glufo were vomiting (4 pts), fatigue (1 pt), and neuritis (1 pt). The most frequently observed adverse reaction was nausea, effecting 13 pts, but not exceeding grade 2. No hematuria was observed. Conclusions: Glufo administered as 2nd line chemotherapy revealed anti-tumor activity in breast cancer pts who had previously received an alkylator. Myelotoxicity toxicity was particularly mild. Monitoring of renal function was required. Taken together, our data indicate activity of Glufo in advanced breast cancer and warrant further investigation. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Threshold Pharmaceuticals Threshold Pharmaceuticals Threshold Pharmaceuticals
Authors' response
Authors: Susan Peters, Hans Kromhout, Ann Olsson, Kurt Straif, Roel Vermeulen
Journal: Thorax (2012)

Response to: Mastrangelo, G., Rylander, R., Cegolon, L. & Lange, J.H. (2012). Lung cancer risk in subjects exposed to organic dust: an unexpected and surprising story. Thorax 67(12), 1112–1112. Original article: Peters, S., Kromhout, H., Olsson, A.C., Wichmann, H.-E., Bruske, I., Consonni, D., Landi, M.T., Caporaso, N., Siemiatycki, J., Richiardi, L., Mirabelli, D., Simonato, L., Gustavsson, P., Plato, N., Jockel, K.-H., Ahrens, W., Pohlabeln, H., Boffetta, P., Brennan, P., Zaridze, D., Cassidy, A., Lissowska, J., Szeszenia-Dabrowska, N., Rudnai, P., Fabianova, E., Forastiere, F., Bencko, V., Foretova, L., Janout, V., Stucker, I., Dumitru, R.S., Benhamou, S., Bueno-de-Mesquita, B., Kendzia, B., Pesch, B., Straif, K., Bruning, T. & Vermeulen, R. (2012). Occupational exposure to organic dust increases lung cancer risk in the general population. Thorax 67(2), 111–116.
Long-Term Risk for Aortic Complications After Aortic Valve Replacement in Patients With Bicuspid Aortic Valve Versus Marfan Syndrome
Authors: Shinobu Itagaki, Joanna P. Chikwe, Yuting P. Chiang, Natalia N. Egorova, David H. Adams
Journal: Journal of the American College of Cardiology (2015)